Replies to post #278297 on Avid Bioservices Inc (CDMO)

[biopharm]

The road back to $5+ begins for Peregrine

[Wernaaa]

Mouse.....preclinical......mouse........preclinical.....

Can we getting more specific.....post-clinical?

[pili2016]

$PPHM To begin rally. Will present several clinical results at SITC this weekend (The Society for Immunotherapy of Cancer):

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126401100

Expect great new$$$$ and rally to begin ahead of upcoming record quarterly revenues:

https://www.earningswhispers.com/epsdetails/pphm


The company said it is on track to generate second quarter revenue in excess of $20.0 million and continues to expect fiscal year manufacturing revenue of $50.0 million to $55.0 million. The current consensus estimate is revenue of $12.5 million for the quarter ending October 31, 2016 and revenue of $52.9 million for the year ending April 30, 2017.

No other clinical stage biotec has revenues as significant as PPHM's (growing at 40%++ CAGR). Together with over $40M cash and no debt, and significant clinical potential PPHM should be trading well North of $1/share now.

Huge upside from these oversold levels

http://seekingalpha.com/article/4012640-peregrine-pharmaceuticals-misunderstood-undervalued-biotech-significant-upside-potential